Neuraminidase amino acids 149 and 347 determine the infectivity and oseltamivir sensitivity of pandemic influenza A/H1N1 (2009) and avian influenza A/H5N1.

[1]  V. Shanthi,et al.  Exploring the Cause of Oseltamivir Resistance Against Mutant H274Y Neuraminidase by Molecular Simulation Approach , 2012, Applied Biochemistry and Biotechnology.

[2]  E. V. Kostina,et al.  Oseltamivir resistance depends on the amino acid at the 273rd position of neuraminidase of influenza a virus (H1N1) circulating in the human population , 2011, Russian Journal of Bioorganic Chemistry.

[3]  Robert V. Swift,et al.  Mechanism of 150-cavity formation in influenza neuraminidase , 2011, Nature communications.

[4]  G. Dbaibo,et al.  Genetic diversity and antiviral drug resistance of pandemic H1N1 2009 in Lebanon. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[5]  R. Russell,et al.  Combinatorial Effect of Two Framework Mutations (E119V and I222L) in the Neuraminidase Active Site of H3N2 Influenza Virus on Resistance to Oseltamivir , 2011, Antimicrobial Agents and Chemotherapy.

[6]  M. Kiso,et al.  Effect of an Asparagine-to-Serine Mutation at Position 294 in Neuraminidase on the Pathogenicity of Highly Pathogenic H5N1 Influenza A Virus , 2011, Journal of Virology.

[7]  P. Buchy,et al.  Neuraminidase Inhibitor Sensitivity and Receptor-Binding Specificity of Cambodian Clade 1 Highly Pathogenic H5N1 Influenza Virus , 2011, Antimicrobial Agents and Chemotherapy.

[8]  Ha T. Nguyen,et al.  Comprehensive assessment of 2009 Pandemic Influenza a (H1N1) Virus Drug Susceptibility in vitro , 2010, Antiviral therapy.

[9]  Jianhua He,et al.  The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site , 2010, Nature Structural &Molecular Biology.

[10]  R. Webster,et al.  Antiviral Susceptibility of Avian and Swine Influenza Virus of the N1 Neuraminidase Subtype , 2010, Journal of Virology.

[11]  D. Baltimore,et al.  Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance , 2010, Science.

[12]  R. Webster,et al.  Competitive Fitness of Oseltamivir-Sensitive and -Resistant Highly Pathogenic H5N1 Influenza Viruses in a Ferret Model , 2010, Journal of Virology.

[13]  J. Taubenberger,et al.  The 1918 influenza pandemic: Lessons for 2009 and the future , 2010, Critical care medicine.

[14]  J. Taubenberger,et al.  Influenza: The Once and Future Pandemic , 2010, Public health reports.

[15]  Thanyada Rungrotmongkol,et al.  Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus. , 2009, Biochemical and biophysical research communications.

[16]  J. Andrew McCammon,et al.  Characterizing Loop Dynamics and Ligand Recognition in Human- and Avian-Type Influenza Neuraminidases via Generalized Born Molecular Dynamics and End-Point Free Energy Calculations , 2009, Journal of the American Chemical Society.

[17]  P. Mitrasinovic,et al.  On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA). , 2009, Biophysical chemistry.

[18]  Alan J. Hay,et al.  Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants , 2008, Nature.

[19]  J. Heesemann,et al.  Contribution of Trimeric Autotransporter C-Terminal Domains of Oligomeric Coiled-Coil Adhesin (Oca) Family Members YadA, UspA1, EibA, and Hia to Translocation of the YadA Passenger Domain and Virulence of Yersinia enterocolitica , 2008, Journal of bacteriology.

[20]  T. Songserm,et al.  Human single-chain antibodies that neutralize homologous and heterologous strains and clades of influenza a virus subtype H5N1 , 2008, Antiviral therapy.

[21]  David J. Stevens,et al.  The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design , 2006, Nature.

[22]  Julie D Thompson,et al.  Multiple Sequence Alignment Using ClustalW and ClustalX , 2003, Current protocols in bioinformatics.

[23]  R. Webster,et al.  Eight-plasmid system for rapid generation of influenza virus vaccines. , 2002, Vaccine.

[24]  W. Pearson,et al.  Current Protocols in Bioinformatics , 2002 .

[25]  H. Klenk,et al.  Functional balance between haemagglutinin and neuraminidase in influenza virus infections , 2002, Reviews in medical virology.

[26]  M. Potier,et al.  Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. , 1979, Analytical biochemistry.

[27]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[28]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[29]  I. Barr,et al.  Oseltamivir Resistance and the H274Y Neuraminidase Mutation in Seasonal, Pandemic and Highly Pathogenic Influenza Viruses , 2012, Drugs.

[30]  Uenza Manu.  WHO Manual on Animal Influenza Diagnosis and Surveillance , 2002 .